Skip to main content
. 2018 Aug 5;2018:8413096. doi: 10.1155/2018/8413096

Table 3.

Management of GPA with end-stage renal disease.

Survey Question Specialty, N Yes, % No, % Unsure, % p-value
Aside from routine considerations of modality, do you PREFER Hemodialysis over Peritoneal Dialysis (PD) because of the risk of infection from immunosuppression on PD? Rheum, 55 9.1 14.5 76.4 P=0.019
Neph, 63 17.4 74.6 7.94

Once a patient is on dialysis, do you try to taper off the immunosuppression earlier than a non-dialysis GPA patient? Rheum, 55 5.5 36.4 58.2 <0.0001
Neph, 60 28.3 70.0 1.7

Do you wait for ANCA titer to become negative before listing for transplant? Rheum, 55 3.6 16.4 80.0 <0.0001
Neph, 59 30.5 55.9 13.6

Do you believe ANCA titer positivity AT THE TIME OF RENAL TRANSPLANT influences graft survival or vasculitis relapse rate? Rheum, 55 7.3 9.1 83.6 <0.0001
Neph, 58 25.8 51.7 22.4

Is your renal transplant INDUCTION immunosuppression for a patient with GPA any different than a non-GPA renal transplant patient? Rheum, 54 3.7 3.7 92.6 <0.0001
Neph, 59 18.6 64.4 17.0

Is your renal transplant MAINTENANCE immunosuppression for a patient with GPA any different than a non-GPA renal transplant patient? Rheum, 55 3.6 3.6 92.7 <0.0001
Neph, 59 20.3 66.1 13.6